

Table S7 – Cochran-Mantel-Haenszel statistics for the primary endpoint successful completion of the study without increase in furosemide dose for the entire per protocol set 2 (PPS2) population and the PPS2 population divided into strata

	Treatment group	N-1	N-2	Odds Ratio	95% CI
All	Pimobendan	30	11	1.019	0.34 – 3.09
	Placebo	29	12		
LVOTO	Pimobendan	8	4	0.625	0.11 – 3.71
	Placebo	13	8		
No LVOTO	Pimobendan	22	7	1.40	0.33 – 5.93
	Placebo	16	4		

Notes: There was no statistical difference between treatments in each group ($P > .05$).

Abbreviations: N-1, all cats. N-2, cats that reached the primary endpoint of successful outcome at D180. CI, confidence interval; LVOTO, left ventricular outflow tract obstruction.